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Background: Globally, 500 million people are chronically infected with Hepatitis B virus (HBV)
and Hepatitis C virus (HCV). While these viruses are notorious for their detrimental effect on
the liver they are also known to affect multiple organs in the body including the lungs.
Aim: To investigate if exposure to HBVandHCV is associatedwith lung function and respiratory dis-
eases.
Methods: Data from the Third National Health and Nutrition Examination Survey (NHANES III) was
analysed using multiple linear regressions to investigate the association between exposure to
HBV and HCV with the various measures of lung function, while multiple logistic regressions were
used to evaluate the association with the respiratory diseases asthma and chronic obstructive pul-
monary disease (COPD).
Results: Exposure to HCVwas significantly associatedwith an increase in Forced Expiratory Volume
in1 s, FEV1 (Coef: 97.94ml, 95%CI: 38.87 to157.01)andFullVitalCapacity, FVC(Coef:90ml,95%CI:
14.50 to 166.24). Individuals who had been exposed to both HBV and HCV also had a significantly
higher FEV1 (Coef: 145.82, CI: 60.68 to 230.94) and FVC (Coef: 195.09, CI: 78.91 to 311.26). There
was also a significant association between exposure to HBV and asthma (OR: 1.28, 95% CI: 1.05 to
1.58). These associations were no longer significant after additionally adjusting for cocaine and
marijuana use as well as poverty income ratio.
Conclusion: Our research implies that hepatotropic viruses may affect the respiratory system, but
more work at a population level is needed to further explore these associations.
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1734 L.Y. Goh et al.BackgroundHepatitis B virus (HBV) and hepatitis C virus (HCV) account
for the majority of chronic blood-borne infections affecting
the liver. Both are major public health problems and are
among the top ten causes of death by infectious diseases
worldwide [1,2]. Currently, 500 million people around the
world are chronically infected with HBV or HCV e this
translates to about 1 in every 12 individuals [3]. Further-
more, co-infection with these viruses is possible due to
similar modes of transfer (eg. blood transfusion, intrave-
nous drug use, sexual contact, percutaneous injuries in a
hospital setting), resulting in a more potent disease
[2,4e7].
While the hepatotrophic effects of HBV and HCV are
well-known, these viruses also produce systemic effects
[8,9]. Research has shown that these infections (HCV in
particular) manifest in several extrahepatic conditions such
as lymphoproliferative, dermatological, nephrological,
neurological, endocrinological, cardiocirculatory and pul-
monary disorders [10e14]. So far, mixed cryoglobulinemia
and non-hodgkin’s lymphoma are the two most common
conditions associated with hepatitis virus infections [15].
There have been many biological mechanisms put forth
as to how viral hepatitis affects the lungs. The effects on
the lung could be direct or indirect. Directly, several
studies and case reports have linked HCV to interstitial lung
disease [16e28], asthma [29,30], COPD [31] and found
these viruses to affect lung function [30,32,33]. Indirect
effects are thought to arise through associated diseases
such as cryologlobulinaemia [21,34e41], liver cirrhosis [42]
or in relation to treatment used for HCV e interferon
therapy, which has been known to cause the development
of pulmonary sarcoidosis, interstitial lung disease and other
pulmonary complications [28,43e61].
An association between systemic viral infections and
lung disease had been suggested some years ago but
despite the increasing numbers of HBV and HCV patients
diagnosed, it has not become an obvious clinical issue
either in the respiratory or gastrointestinal clinics
[16e19,62]. Furthermore, research in this area has been
very mixed and has largely been in the form of case reports.
Much research on this topic has focused on the effect of
HCV on the lung while HBV or HBVeHCV co-infection has not
been considered. There is also very limited literature on
whether HBV or HCV infection is associated with COPD or
asthma. To examine whether earlier findings of an associ-
ation imply a bias in reported studies or if this association
just being missed in clinical practice, we have performed a
population based study utilising objective spirometric
measures of lung function and questionnaires to identify
respiratory diseases.
Methods
Study population
This research was secondary analysis study conducted using
data from the Third National Health and Nutrition Exami-
nation Survey (NHANES III). The NHANES III is a series of
surveys conducted of the U.S. non-institutionalisedpopulation carried out between 1988 and 1994 [63]. Full
details of the examination and survey procedures have
been published by the National Centre for Health Statistics
[63]. All participants aged over 17 years of age were
included in the analysis, provided they had complete data
for relevant exposures, outcomes, and confounding factors.
Institutional Review Board (IRB) approval and documented
consent was obtained from participants [64].
Data collection
Questionnaire data was collected by trained interviewers
who gathered information on age, sex, race/ethnicity,
medical history, socioeconomic status, smoking history and
illicit drug use history. Participants attended a mobile ex-
amination unit where all anthropometric measurements
were taken: height, weight, waist measurements and hip
measurements. Blood samples were taken for biochemical
assays [65]. Spirometric measurements were taken to pro-
vide data on FEV1 and FVC [66].
Statistical analyses
Participants were classified into three groups based on their
self-reported smoking history: never-smokers, current
smokers and ex-smokers. Total cigarette smoking was
quantified in terms of pack-years. The ratio of FEV1 to FVC
was calculated: FEV1/FVC. Asthma was defined as self-
reported physician-diagnosed asthma [65]. Chronic
Obstructive Pulmonary Disease was defined using the Global
Initiative for Chronic Obstructive Lung Disease (GOLD)
spirometry criteria: FEV1/FVC < 70% and FEV1 < 80%
percent-predicted (percentage of the average expected of
someone of your height, age, sex and race) [66]. COPD was
also defined through the self-reporting of participants on
being diagnosed by a physician with emphysema and/or
chronic bronchitis [9,66]. Hepatitis B core antibody (anti-
HBc) positivity was used to determine exposure to HBV,
while Hepatitis B surface antigen (HBsAg) positivity showed
infection with HBV [67]. Hepatitis C antibody (anti-HCV)
positivity was used to determine exposure to HCV [6,68].
The poverty income ratio (PIR) was calculated as a ratio of
the midpoint of the observed family income category to the
poverty threshold [65]. Body mass index (BMI) was calcu-
lated: weight (kg)/height (m2). Waist to Hip ratio was
calculated: waist circumference/hip circumference. Total
cocaine and marijuana usage in the participant’s lifetime
was also taken into account e this was only measured in
patients aged 18e60 years old.
The associations of HBV and HCV infection with COPD
and asthma were analysed using a multiple logistic regres-
sion model and the baseline model included adjustments
for the following a priori confounders: age, sex, race-
ethnicity and smoking history (status and years of smoking).
BMI, waist: hip ratio, cocaine and marijuana use as well as
poverty income ratio were also checked and added to the
baseline model if they changed the regression coefficient or
odds ratio by 10% or more when added to the model. The
associations of HBV and HCV infection with FEV1, FVC and
FEV1: FVC were analysed using a multiple linear regression
models and adjusted for the a priori confounders: age, sex,
Table 1 Demographic characteristics of the study population and of subjects excluded from the study.
Characteristic Baseline population (n Z 14,055) Restricted study Populationb (n Z 9159) Excluded subjectsa (n Z 5995)
Mean (SDc) No. % Mean (SDc) No. % Mean (SDc) No. %
Sex
Male 6609 47.0 4226 46.1 2792 46.6
Female 7446 53.0 4933 53.8 3203 53.4
Age (Years) 45.23 (19.58) 35.16 (11.64) 53.02 (22.48)
Smoking status
Never smoker 7316 52.0 4897 53.5 2917 48.8
Ex-smoker 3182 22.7 1582 17.3 1621 27.2
Current smoker 3557 25.3 2680 29.3 1433 24.0
Race/ethnicity
Non-Hispanic white 6007 42.7 3384 37.0 2476 41.3
Non-Hispanic black 4017 28.6 2941 32.1 1469 24.5
Mexican-American 4031 28.7 2834 30.9 1275 21.3
Other 0 0.0 0 0.0 775 12.9
Height (cm) 166.79 (9.78) 167.77 (9.60) 164.60 (10.20)
Body mass indexd 26.98 (5.76) 26.91 (6.02) 26.62 (6.18)
Waist:hip ratio 0.92 (0.09) 0.89 (0.09) 0.92 (0.09)
FEV1 (L)
c 3.00 (0.95) 3.31 (0.83) 2.76 (1.00)
FVC (L)c 3.79 (1.10) 4.08 (1.01) 3.48 (1.15)
FEV1:FVC ratio 0.79 (0.10) 0.82 (0.08) 0.79 (0.11)
COPD 1662 11.8 702 7.7 298 15.0
Asthma 971 6.9 654 7.1 405 6.8
Anti-HBc positive 971 6.9 532 5.8 296 15.0
HBsAg positive 45 0.3 35 0.4 29 1.1
Anti-HCV positive 325 2.3 256 2.8 65 2.5
Anti-HBc and Anti-HCV 117 0.9 96 1.1 32 1.5
Positive
Cocainee
Don’t use 8109 88.5 8109 88.5 2553 90.1
1 or 2 times 274 3.0 274 3.0 75 2.7
3 to 10 times 333 3.6 333 3.6 91 3.2
11 to 99 times 292 3.2 292 3.2 78 2.8
100 or more 151 1.7 151 1.7 38 1.3
Marijuanae
Don’t use 5536 60.4 5536 60.4 1911 67.4
1 or 2 times 736 8.0 736 8.0 216 7.6
3 to 10 times 1104 12.1 1104 12.1 271 9.6
11 to 99 times 901 9.9 901 9.9 232 8.2
100 or more 882 9.6 882 9.6 205 7.2
Poverty income ratioe 2.40 (1.76) 2.40 (1.76) 2.36 (1.78)
a Data were missing for some excluded subjects.
b Sample with data for additional confounders cocaine and marijuana use and poverty income ratio.
c SD, standard deviation; FEV1, forced expiratory volume in 1 s; FVC, forced vital capacity.
d Weight (kg)/height (m2).
e n Z 9159 for the study population and restricted study population and n Z 2835 for the excluded group.
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of smoking) and similar additional confounders as before.
The data analysis was carried out using STATA version 11.Results
From the total study population of 20,050 subjects aged 17
to 90 over years who provided data for the NHANES III
survey, 14,055 people met the inclusion criteria for thebaseline model (including a priori confounders). After
eliminating a further 4896 individuals for missing data on
the additional confounders, marijuana use, cocaine use and
poverty-income ratio, the restricted study population
model was 9159 people (Table 1).
The demographics and other characteristics of the sub-
jects in the study population and excluded group were very
similar except that the excluded subjects were on average
about 8 years older than the included subjects. Among the
study population, the prevalence of COPD was 11.8%, anti-
Table 2 Association of hepatitis B and hepatitis C serum markers with lung function and respiratory diseases.
FEV1
Serum markers Baseline population (n Z 14,055) Restricted population (n Z 9159)
FEV1 Coef. (mL) 95% CI
a FEV1 Coef. (mL) 95% CI
a
Anti-HBc 5.96b 36.66 to 24.73 12.76 64.68 to 39.15
HBsAg 3.15 174.86 to 168.56 27.98 148.03 to 203.99
Anti-HCV 97.94 38.87 to 157.01 46.87 12.64 to 106.38
Anti-HCV & Anti-HBc 145.81b 60.68 to 230.94 72.13 32.77 to 177.03
FVC
Serum markers Baseline population (n Z 14 055) Restricted population (n Z 9159)
FVC Coef. (mL) 95% CIa FVC Coef. (mL) 95% CIa
Anti-HBc 17.97 53.21 to 17.49 26.95 81.02 to 27.12
HBsAg 18.91 236.01 to 198.16 35.65 272.58 to 166.21
Anti-HCV 90.37 14.50 to 166.24 83.50 35.24 to 104.55
Anti-HCV & Anti-HBc 195.09b 78.91 to 311.26 53.19 33.64 to 200.64
FEV1:FVC
Serum markers Baseline population (n Z 14 055) Restricted population (n Z 9159)
FEV1:FVC Ratio Coef. (%) 95% CI
a FEV1:FVC Ratio Coef. (%) 95% CI
a
Anti-HBc 0.02b 0.53 to 0.56 0.08 0.72 to 0.88
HBsAg 0.88 0.11 to 1.88 0.50 0.41 to 1.42
Anti-HCV 0.02b 1.54 to 1.57 0.40 0.81 to 1.62
Anti-HCV & Anti-HBc 0.69 3.42 to 2.41 1.30e 0.66 to 3.25
Asthma
Serum markers Baseline population (n Z 14 055) Restricted population (n Z 9159)
Odds ratio 95% CIa Odds ratio 95% CIa
Anti-HBc 1.28 1.03 to 1.58 1.33e 0.97 to 1.81
HBsAg 1.56 0.66 to 3.37 1.16e 0.38 to 3.53
Anti-HCV 1.20 0.84 to 1.72 0.99c 0.60 to 1.63
Anti-HCV & Anti-HBc 1.68 0.97 to 2.94 1.20d 0.57 to 2.53
Chronic obstructive pulmonary disease (COPD)
Serum Markers Baseline (n Z 14 055)
Odds ratio 95% CIa
Anti-HBc 1.00 0.81 to 1.24
HBsAg 1.35 0.49 to 3.69
Anti-HCV 0.91 0.61 to 1.35
Anti-HCV & Anti-HBc 0.95 0.57 to 1.60
Study population: Results were adjusted for age, sex, height, smoking (status and pack-years), and race/ethnicity.
Restricted Study Population: Results were additionally adjusted for cocaine and marijuana use as well as poverty income ratio.
a CI, Confidence Interval.
b Adjusted for BMI and Waist: Hip ratio.
c Adjusted for marijuana use.
d Adjusted for cocaine and marijuana use.
e Not adjusted for additional confounders.
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was 2.3% and the prevalence both anti-HBc positive and
anti-HCV positive was 0.9%. The excluded group had a
higher percentage of subjects who had COPD (15%), were
anti-HBc positive (15%), HBsAg positive (1.1%), anti-HCV
(2.5%) and positive for both anti-HBc and anti-HCV (1.5%)
compared to the study population (Table 1).
Individuals positive for anti-HCV showed a significant
increase of nearly 100 ml (95% CI: 38.87 to 157.01) of FEV1
and a significant rise of 90 ml (95% CI: 14.50 to 166.24) ofFVC in the study population. Similarly in individuals positive
for both anti-HCV and anti-HBc there was a significant in-
crease of 145 ml (95% CI: 60.68 to 230.94) of FEV1 and
195 ml of FVC (95%: 78.91 to 311.26) in the study population
but not in the restricted study population in which there
was additional adjustment for cocaine and marijuana use as
well as poverty income ratio (Table 2).
Individuals positive for anti-HBc were 28% more likely
to have asthma than an individual negative for anti-HBc
(95% CI: 1.05 to 1.58) and this relationship was again
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restricted study population (Table 2). There were no sig-
nificant associations noted with any of the markers of
exposure with FEV1:FVC ratio and COPD in either popu-
lation (Table 2).Discussion
Hitherto, there have been no large-scale population studies
looking at the association between hepatitis viral infections
with lung function and disease. The strengths of this study
include a large representative sample, and a high response
rate e 86% of the invited individuals chose to participate in
the questionnaire survey and 78% of the invited individuals
participated in the medical examination. A subset of the
study population was created as a restricted study popu-
lation because it was felt that the additional confounders
of marijuana use, cocaine use and poverty income ratios
needed to be considered. Marijuana and cocaine are often
used concurrently with both smoking and intravenous drug
use. We were unfortunately unable to adjust for intrave-
nous drug use as a confounder as there was insufficient data
on the NHANES III.
The main findings of the study were that individuals
positive for anti-HCV as well as both anti-HBc and anti-
HCV had a significant increase in FEV1 and FVC. In-
dividuals who were anti-HBc positive also had a signifi-
cantly increased risk of asthma. Our findings are in
contradiction to each other as asthma is an obstructive
respiratory disease and is characterised spirometrically
by a decrease in lung function. The findings that exposure
to HCV and HBV are associated with higher lung function
is very surprising, however this was only in the model
which adjusts for age, sex, height, smoking (status and
pack-years), and race/ethnicity. When you further adjust
for drug use and social class this effect disappears,
therefore suggesting that the initial results possible arose
due to confounding. We also found HBV to be associated
with asthma. This is a new finding as no previous studies
have focused on HBV infection and asthma. Nevertheless,
this association was again not significant in the restricted
study population.
A limitation of this study lies in the identification of
asthma and COPD. Firstly, the NHANES III database con-
tains a limited number of respiratory questions used to
identify both asthma and COPD compared to later NHANES
questionnaire iterations. Indeed several epidemiological
studies such as the European Community Respiratory
Health Survey and International study of Asthma and Al-
lergy in Childhood commonly identify asthma on the basis
of symptoms and/or treatment in an attempt to avoid
exclusion. Having said that, we also note that the symp-
toms of asthma are not completely specific to the condi-
tion and it is difficult to identify asthma purely on the
basis of symptoms. A more certain way of diagnosing
asthma in the future would be to use a combination of
spirometry, medical history, and a physical examination.
Secondly, asthma and COPD are prone to considerable
variability and it is possible that lung function testing may
have occurred after successful treatment, during well or
poorly controlled periods of the disease. Furthermore, alarge population of asthmatics can be described as
intermittent, with generally normal lung function. Just
looking at the general population at large there is a
considerable variability of lung function.
The anti-HBc, HBsAg and anti-HCV markers were objec-
tive measures for establishing either an exposure to HBV or
HCV therefore eliminating misclassification bias. However,
this is not ideal as we would have preferred a more detailed
clinical picture of our subjects. Purely based on the
serology results, we were unable to discern the HBV or HCV
status of the individual (acute, chronic, resolved infection
or vaccination against HBV) at the time the blood was
taken. Furthermore we do not know if the subjects have
undergone treatment for their disease specifically treat-
ment with interferons e which has been known to cause the
development of pulmonary sarcoidosis and interstitial lung
disease [29,43e48]. In more recent NHANES surveys, poly-
merase chain reaction has been used for confirmation and
blood results for alanine aminotransferase, aspartate
aminotransferase and alkaline phosphatase which could
potentially be used as a proxy for liver pathology. An even
better marker would be liver biopsies to confirm liver
cirrhosis.
Views on the subject matter have been very mixed but
the results of this exploratory study serves to add to the
growing body of research. Three previous studies have
found that hepatitis C infection is associated with
decreased lung function. A small prospective cohort study
reported that the decline of FEV1 was greater in COPD pa-
tients who had HCV infection than in those who were HCV
negative [30]. However, almost half of the HCV patients had
received interferon treatment, which may have caused a
confounding effect on the result of the study. Another
prospective observational study by Erturk et al. demon-
strated that HCV-infection was associated with decreased
FEV1 and FVC readings [32]. However, these findings were
possibly subject to much bias and confounding as the
sample size (20 individuals) was very small and was not
adjusted for any confounders. Furthermore, 12 of the
participants had received therapy of inteferon and ribavirin
for HCV infection. A separate observational study which
looked at 178 non-cirrhotic patients with chronic viral
hepatitis found no significant impairment of FEV1 and FVC
[33].
Three studies have been carried out with respect to
COPD and viral hepatitis. The first, a large study carried out
in Japan by Minakata et al. found no significant association
between HCV infection and COPD [69]. A second by Silva
et al. and third study by Kanazawa et al. showed otherwise,
the former found a higher prevalence of COPD in HCV
positive individuals compared to HCV-negative individuals
and the latter found that HCV infections increased the rate
of deterioration of lung function in patients with COPD
compared to patients not infected with HCV [30,31]. In the
study by Silva et al. selection was from hospital outpatients
and only 68% of the participants had co-morbidities while
the population in the Minakata et al. study were specifically
selected individuals who had chronic diseases other than
respiratory diseases. The difference in the criteria of se-
lection will have made the two study populations not
directly comparable and may explain the discrepancy in the
results. The third study is not comparable to the other
1738 L.Y. Goh et al.studies as it was a longitudinal study as opposed to a cross-
sectional one.
Conclusion
There has been much interest in viral hepatitis and its ef-
fects on the lung. However, the research has been incon-
clusive. Nevertheless, there has been an overall increased
appreciation that viral hepatitis infection results in respi-
ratory manifestations that lead to additional morbidity
[16e19,31]. Studies of viral hepatitis may result in
enhanced understanding of its pathophysiology and its ef-
fects on multiple organ systems including the lungs. This
information can then be tailored to create targeted in-
terventions to benefit the individual patient. This is the first
large-scale population based study to look at the associa-
tion of viral hepatitis infection with lung function and res-
piratory disease. We found associations between exposure
to HBV and HCV with changes to lung function as well as a
significant association between HBV and asthma in this
large cross-sectional study. The latter is a novel finding as
no studies have been carried out specifically with subjects
exposed to HBV infection in relation to asthma. Previous
studies have only discussed the impact of HCV infection on
the way asthmatic patients respond to various bronchodi-
lators [29,30]. Furthermore, our study has highlighted the
importance of involving objective measures for both the
hepatitis infections and pulmonary disease. Our research
implies that hepatotropic viruses may affect the respiratory
system, but more work at a population level is needed to
further explore these associations.
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